Clinical Trials Logo

Diabetic Nephropathy clinical trials

View clinical trials related to Diabetic Nephropathy.

Filter by:

NCT ID: NCT02502071 Completed - Type 1 Diabetes Clinical Trials

Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes

Alk-UA
Start date: January 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1 diabetes.

NCT ID: NCT02501772 Recruiting - Clinical trials for Diabetic Nephropathy

The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy

Start date: September 2014
Phase: N/A
Study type: Interventional

For diabetic patient with persisted albuminuria under the intensive control on blood pressure and blood glucose, the non-invasive method of acupressure at Sanyinjiao (SP6) is easy to use and significantly effect on albuminuria reduction in patients of diabetic nephropathy.

NCT ID: NCT02477163 Completed - Clinical trials for Diabetic Nephropathy

Ayurvedic Management of Chronic Kidney Disease

Start date: January 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of multi-dimentional ayurvedic treatment in the patients of various types of chronic kidney disease.

NCT ID: NCT02410499 Withdrawn - Clinical trials for Diabetic Nephropathy

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Start date: May 20, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the effects of 85 days treatment with MLN1202 on urinary albumin-to-creatinine ratio (UACR) in participants with type 2 diabetes, advanced kidney disease/diabetic nephropathy (DN) and macro-albuminuria (UACR>300 mg/g) based on average of 3 consecutive first morning voids sample collection.

NCT ID: NCT02409511 Recruiting - Clinical trials for Diabetic Retinopathy

Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)

Start date: January 2016
Phase: N/A
Study type: Observational

Microalbuminuria (MA) is an independent cardiovascular risk factor in diabetic and non-diabetic subjects. However, in the setting of type 2 diabetes, microalbuminuria could be a marker of either early diabetic nephropathy or diffuse endothelial dysfunction. At present, there are no biomarkers that permit us to discriminate between these two conditions.

NCT ID: NCT02384902 Completed - Clinical trials for Diabetic Nephropathy

Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients

Start date: May 2014
Phase: N/A
Study type: Interventional

low GI and low GL diet have more beneficial effect for diabetic nephropath patients compared with conventional diet. low GL may have more favorable effect than low GI diet.

NCT ID: NCT02345057 Completed - Clinical trials for Diabetic Nephropathy

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate efficacy and safety of different doses of CS-3150 compared to placebo in Japanese Type 2 Diabetes Mellitus and Microalbuminuria. The Primary endpoint is the change from baseline in urinary albumin to creatine ratio (UACR).

NCT ID: NCT02327754 Completed - Clinical trials for Diabetic Nephropathy

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout

UPWARD
Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout. Participants are randomized to placebo (n=20) or topiroxostat (n=40) for 28 weeks. The investigational drugs for this study are supplied by FUJI YAKUHIN CO., LTD.

NCT ID: NCT02276196 Completed - Diabetes Mellitus Clinical Trials

Effect of LIXIsenatide on the Renal System

ELIXIRS
Start date: September 2014
Phase: Phase 4
Study type: Interventional

Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, may hold promise in preventing the onset and progression of diabetic kidney disease. However, the potential renoprotective effects of these agents, that are believed to be effectuated "beyond glucose control", have not been sufficiently detailed in human diabetes. Therefore, the present study aims to explore the mechanistic and clinical effects of GLP-1 receptor agonists on renal physiology and biomarkers in patients with type 2 diabetes. Forty patients with insulin-treated type 2 diabetes will undergo an eight week intervention with lixisenatide or insulin glulisine in order to assess changes in the outcome parameters.

NCT ID: NCT02251067 Completed - Clinical trials for Diabetic Nephropathy

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

Start date: September 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.